Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Optivia Wins DDI Grant

April 6, 2011 7:57 am | News | Comments

Optivia Biotechnology Inc. has received a $1.85 million federal grant to determine the precise mechanisms that underlie certain drug-to-drug interactions, in an effort to help improve medication safety.

TOPICS:

ImmunoSite Working With Beckman Coulter

April 6, 2011 7:52 am | News | Comments

ImmunoSite Technologies, LLC, a provider of immune monitoring services, is now receiving direct customer referrals for particle testing services from Beckman Coulter, Inc. as part of a recent collaboration agreement.

TOPICS:

Depression Linked to Aged Immune Cells

April 6, 2011 7:45 am | News | Comments

According to new findings, certain cases of major depression are associated with premature aging of immune cells, which may make people more susceptible to other serious illness.

TOPICS:
Advertisement

More Salt Could Mean Less Stress

April 6, 2011 7:40 am | News | Comments

All those salty snacks available at the local tavern might be doing more than increasing your thirst: They could also play a role in suppressing social anxiety.

TOPICS:

BMS Releases HCV Trial Results

April 6, 2011 7:37 am | News | Comments

PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response in genotypes 1, 2, 3, and 4 than the standard regimen of PEG-Interferon alfa and ribavirin in treatment-naïve patients chronically infected with hepatitis C.

TOPICS:

C3BS Presents Stem Cell Trial Data

April 6, 2011 7:30 am | News | Comments

Belgian biotechnology company, Cardio3 BioSciences, presented detailed data from the Phase 2 clinical trial of C3BS-CQR-1 (C-Cure), its novel stem cell therapy for ischemic cardiomyopathy.

TOPICS:

Interferon-fused Antibody Increases Tumor Retention

April 6, 2011 7:24 am | News | Comments

Immunomedics, Inc. announced results from a preclinical study of C2-2b-2b, a new protein construct created by the company's dock-and-lock method for protein engineering. C2-2b-2b is an immunocytokine that targets the HLA-DR antigen.

TOPICS:

Data Shows OGX-427 Inhibits Hsp27

April 6, 2011 7:15 am | News | Comments

OncoGenex Pharmaceuticals, Inc. announced that preclinical data utilizing their pipeline compound OGX-427 demonstrated the ability of the drug candidate to inhibit Heat Shock Protein 27.

TOPICS:
Advertisement

Researchers Develop Screen for Anticancer Drug Targets

April 6, 2011 7:09 am | News | Comments

Tumor suppressor genes normally control the growth of cells, but cancer can spring up when these genes are silenced by certain chemical reactions that modify chromosomes.

TOPICS:

Nanopolymer May Reduce Chemo Side Effects

April 6, 2011 7:06 am | News | Comments

A biochemist has developed a nanopolymer that can be coated with drugs, enter cells and then be removed to determine which proteins in the cells the drug has entered, which may help reduce drug side effects.

TOPICS:

Strawberries May Help Prevent Esophageal Cancer

April 6, 2011 6:55 am | News | Comments

Eating strawberries may be a way to help people at risk of esophageal cancer protect themselves from the disease, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center.

TOPICS:

Valeant Proposes New Cephalon Board

April 6, 2011 6:50 am | News | Comments

Valeant Pharmaceuticals named its own slate of directors for Cephalon as part of its hostile takeover bid. Cephalon Inc. recently rejected an unsolicited, $5.7 billion offer from Canada's Valeant.

TOPICS:

Prochieve Cuts Preterm Births in Half

April 6, 2011 6:45 am | by Lauran Neergaard | News | Comments

A simple treatment - a hormone-containing vaginal gel - significantly reduces premature births among pregnant women who are at high risk because of a problem with the cervix, government researchers reported.

TOPICS:

Detecting Multiple miRNA Markers with Microarrays

April 5, 2011 10:40 am | by John Keefe, Sr. Product Manager-RNA; Affymetrix, Santa Clara, Calif. | Articles | Comments

Small non-coding RNA has become a very important class of molecules for understanding cellular development, differentiation, and the mechanisms of disease for genetic disorders such as cancer.

TOPICS:

Small RNA Discovery and Profiling with Next-Generation Sequencing

April 5, 2011 10:32 am | Articles | Comments

As next-generation sequencing continues to evolve as a research tool, it is being adopted for examining gene regulation at the transcriptional and post-transcriptional levels.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading